Program: Spotlight Sessions
Session: Immunotherapies for myeloid neoplasms: are we ready for primetime?
Session: Immunotherapies for myeloid neoplasms: are we ready for primetime?
Monday, December 12, 2022, 2:45 PM-4:00 PM
Disclosures: Assouline: Genentech/Roche, Astra Zeneca, Novartis, BMS, Jazz, Gilead, Amgen, Beigene, Abbvie, Paladin: Consultancy, Honoraria; Novartis: Research Funding.
See more of: Immunotherapies for myeloid neoplasms: are we ready for primetime?
See more of: Spotlight Sessions
See more of: Spotlight Sessions
Previous Presentation
|
Next Presentation >>